IDEAYA Biosciences Inc.
Last updated September 27, 2026
Organization details
- Legal name
- IDEAYA Biosciences Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- IDYA
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001676725
- EIN
- 47-4268251
Board of directors
-
Catherine J. Mackey · DirectorSince 2023
-
Jeffrey Stein · DirectorSince 2023
-
Malcolm Garret Hampton · DirectorSince 2023
- Since 2023
-
Susan L. Kelley · DirectorSince 2023
-
Terry J. Rosen · DirectorSince 2023
-
Timothy M. Shannon · DirectorSince 2023
-
Wendy L. Yarno · DirectorSince 2023
-
Yujiro S. Hata · Director · President and CEOSince 2023
Chief executives
Yujiro S. Hata
· President and CEO
Dates unknown
Director election results
Annual meeting of June 16, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
77.7%
-
96.3%
-
96.6%
Board connections
7 of this board's directors also sit on 11 other boards.
- via Scott W. Morrison and Wendy L. Yarno
- via Terry J. Rosen
- via Scott W. Morrison
- via Susan L. Kelley
- via Yujiro S. Hata
- via Wendy L. Yarno
- via Wendy L. Yarno
- via Malcolm Garret Hampton
- via Scott W. Morrison
- via Catherine J. Mackey
- via Scott W. Morrison
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,648,000
- 1 purchase by 1 insider
- Sold, last 12 months
- $382,131
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 7, 2026 | Ruiz Briseno Andres Officer (Chief Accounting Officer) | Option exercise | +9,550 | $12.86 | $122,813 |
| Jul 7, 2026 | Ruiz Briseno Andres Officer (Chief Accounting Officer) | Open-market sale | −9,550 | $40.01 | $382,131 |
| Mar 2, 2026 | Jeffrey Stein Director | Open-market purchase | +50,000 | $32.96 | $1,648,000 |
| Nov 28, 2025 | Snyder Douglas B. Officer (SVP, General Counsel) | Grant or award | +1,041 | $16.91 | $17,603 |
| Nov 28, 2025 | Ruiz Briseno Andres Officer (See Remarks) | Grant or award | +1,253 | $16.91 | $21,188 |
| May 30, 2025 | Snyder Douglas B. Officer (SVP, General Counsel) | Grant or award | +1,039 | $16.91 | $17,569 |
| Feb 18, 2025 | Yujiro S. Hata Director, Officer (President and CEO) | Option exercise | +12,808 | $19.52 | $250,012 |
| Nov 29, 2024 | Ruiz Briseno Andres Officer (See Remarks) | Grant or award | +682 | $23.26 | $15,863 |
| Jun 27, 2024 | Throne Jason Officer (Chief Legal Officer) | Option exercise | +6,424 | $13.34 | $85,696 |
| Jun 27, 2024 | Throne Jason Officer (Chief Legal Officer) | Option exercise | +47,060 | $7.01 | $329,891 |
| May 29, 2024 | WHITE MICHAEL ANTHONY Officer (Chief Scientific Officer) | Option exercise | +28,500 | $12.86 | $366,510 |
| May 29, 2024 | WHITE MICHAEL ANTHONY Officer (Chief Scientific Officer) | Open-market sale | −27,649 | $36.23 | $1,001,723 |
| May 29, 2024 | WHITE MICHAEL ANTHONY Officer (Chief Scientific Officer) | Open-market sale | −851 | $36.78 | $31,300 |
| May 16, 2024 | Yujiro S. Hata Director, Officer (President and CEO) | Option exercise | +34,433 | $4.31 | $148,406 |
| May 16, 2024 | Yujiro S. Hata Director, Officer (President and CEO) | Open-market sale | −30,084 | $41.73 | $1,255,405 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.